Dudzisz-Śledź, Monika
Bylina, Elżbieta
Teterycz, Paweł
Rutkowski, Piotr
Article History
Accepted: 1 February 2021
First Online: 2 March 2021
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Monika Dudzisz-Śledź has received a speaker honorarium from Pierre Fabre, Merck KGaA, Sanofi Aventis, Novartis, and BMS; has received financial support for attending symposia from Novartis; and has consulted for Merck KGaA and Novartis. Piotr Rutkowski has received an educational grant from Pfizer and a speaker honorarium from Novartis, Pierre Fabre, Eli Lilly, Merck, Sanofi, MSD, and BMS, and has served as a member of the advisory board for MSD, Pierre Fabre, Sanofi, Merck, Novartis, and BMS. Paweł Teterycz and Elżbieta Bylina have no conflicts of interest that might be relevant to the contents of this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MD-Ś, EB, PT, PR created the idea for the article. MD-Ś, EB, PT conducted the literature search and data analysis and drafted the work. PR critically revised and supervised the work.
: Not applicable.